QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATE

被引：7
|
作者：
Wedzicha, Jadwiga A. [1 ]
Price, David [2 ]
Mezzi, Karen [3 ]
Fogel, Robert [4 ]
Banerji, Donald [4 ]
机构：
[1] Imperial Coll London, Natl Heart & Lung Inst, London, England
[2] Univ Aberdeen, Primary Care Resp Med, Aberdeen, Scotland
[3] Novartis Pharma AG, Resp, Basel, Switzerland
[4] Novartis Pharmaceut, Resp, E Hanover, NJ USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷
关键词：
COPD; -; management; Bronchodilators; exacerbations;
D O I：
10.1183/13993003.congress-2015.PA1005
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA1005
引用
收藏
页数：3
相关论文
共 35 条
  • [1] Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
    Zhong, Nanshan
    Wang, Changzheng
    Zhou, Xiangdong
    Zhang, Nuofu
    Patalano, Francesco
    Humphries, Michael
    Wang, Linda
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [2] LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
    Zhong, Nanshan
    Wang, Changzheng
    Zhou, Xiangdong
    Zhang, Nuofu
    Humphries, Michael
    Wang, Linda
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 1015 - 1026
  • [3] Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis
    Vogelmeier, Claus
    Zhong, Nanshan
    Mezzi, Karen
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [4] Comparison of COPD Exacerbations With Once-Daily QVA149 Versus Twice-Daily Salmeterol/Fluticasone Combination: The ILLUMINATE Study
    Bateman, Eric
    Vogelmeier, Claus
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [5] COMPARISON OF COPD EXACERBATIONS WITH ONCE-DAILY QVA149 VERSUS TWICE-DAILY SALMETEROL/FLUTICASONE COMBINATION: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E. D.
    Chen, H.
    Banerji, D.
    THORAX, 2013, 68 : A184 - A185
  • [6] Efficacy And Safety Of Qva149 Compared With Salmeterol/fluticasone Combination In Chinese Patients With Moderate To Severe COPD: A Subgroup Analysis From The Lantern Study
    Zhong, N.
    Wang, C.
    Zhou, X.
    Zhang, N.
    Patalano, F.
    Humphries, M.
    Wang, L.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [7] QVA149 SIGNIFICANTLY IMPROVES LUNG FUNCTION AND SYMPTOMS COMPARED TO TWICE-DAILY FLUTICASONE/SALMETEROL IN COPD PATIENTS: THE ILLUMINATE STUDY
    Kurstjens, N. P.
    Frenzel, C.
    Bateman, E.
    Vogelmeier, C.
    Banerji, D.
    RESPIROLOGY, 2013, 18 : 58 - 58
  • [8] Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study
    Vogelmeier, Claus
    Bateman, Eric
    Pallante, John
    Bryant, Hannah
    Alagappan, Vijay
    D'Andrea, Peter
    He, Ellie
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [9] Once-Daily Qva149 Improves Breathlessness And Reduces Rescue Medication Use Compared To Twice-Daily Salmeterol/fluticasone In Patients With COPD: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [10] Once-Daily Qva149 Demonstrates Superior Lung Function Compared To Twice-Daily Salmeterol/fluticasone In All Subgroups Of COPD Patients: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
1234